JCB logo
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online 14 January 2002. doi:10.1083/jcb.200111080
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 377K)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dabovic, B.
Right arrow Articles by Rifkin, D. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dabovic, B.
Right arrow Articles by Rifkin, D. B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

© The Rockefeller University Press, 0021-9525/2002/1/227 $5.00
The Journal of Cell Biology, Volume 156, Number 2, January 21, 2002 227-232

Report

Bone abnormalities in latent TGF-ß binding protein (Ltbp)-3–null mice indicate a role for Ltbp-3 in modulating TGF-ß bioavailability



Branka Dabovic1, Yan Chen1, Cristina Colarossi1, Hiroto Obata1, Laura Zambuto1, Mary Ann Perle2 and Daniel B. Rifkin1,3

1 Department of Cell Biology, New York University School of Medicine, New York, NY 10016
2 Department of Pathology, New York University School of Medicine, New York, NY 10016
3 Department of Medicine, New York University School of Medicine, New York, NY 10016

Address correspondence to B. Dabovic, Dept. of Cell Biology, New York University Medical School, 550 First Ave., New York, NY 10016. Tel.: (212) 263-5327. Fax: (212) 263-0595. E-mail: dabovb01{at}med.nyu.edu

The TGF-ßs are multifunctional proteins whose activities are believed to be controlled by interaction with the latent TGF-ß binding proteins (LTBPs). In spite of substantial effort, the precise in vivo significance of this interaction remains unknown. To examine the role of the Ltbp-3, we made an Ltbp-3–null mutation in the mouse by gene targeting. Homozygous mutant animals develop cranio-facial malformations by day 10. At 2 mo, there is a pronounced rounding of the cranial vault, extension of the mandible beyond the maxilla, and kyphosis. Histological examination of the skulls from null animals revealed ossification of the synchondroses within 2 wk of birth, in contrast to the wild-type synchondroses, which never ossify. Between 6 and 9 mo of age, mutant animals also develop osteosclerosis and osteoarthritis. The pathological changes of the Ltbp-3–null mice are consistent with perturbed TGF-ß signaling in the skull and long bones. These observations give support to the notion that LTBP-3 is important for the control of TGF-ß action. Moreover, the results provide the first in vivo indication for a role of LTBP in modulating TGF-ß bioavailability.

Key Words: latent TGF-ß binding protein; TGF-ß; osteoarthritis; osteosclerosis; synchondroses


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents